Skip to main navigation Skip to search Skip to main content

Chemoenzymatic synthesis of human natural killer-1-containing glycans and application as serum antibodies probes

  • Erasmus University Rotterdam

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Despite the versatility of enzyme-mediated oligosaccharide assembly, it has as a limitation that not all glycosyl transferases or glycan-modifying enzymes are readily available to install all natural occurring terminal epitopes. Here a chemoenzymatic strategy is described in which a core oligosaccharide is assembled enzymatically that is subjected to chemical manipulations to install complex terminal epitopes. It provided an unprecedented panel of human natural killer-1 (HSO3–3GlcAβ1–3Galβ1–4GlcNAc)-containing oligosaccharides and derivatives thereof. The compounds were printed as a microarray to examine binding specificities of serum antibodies of patients suffering from anti-myelin-associated glycoprotein neuropathy. All samples required glucuronic acid for antibody binding; however, variable dependence was observed for the length of the LacNAc chain and sulfation of glucuronic acid. Most serum samples required a lacto-neohexaose backbone indicating glycosphingolipids are being targeted. The clinical spectrum of immunoglobulin M monoclonal gammopathy varies, and the glycan microarray provides a more reliable platform for disease diagnosis and prognosis. [Figure not available: see fulltext.]

Original languageEnglish
Pages (from-to)85-98
Number of pages14
JournalNature Synthesis
Volume3
Issue number1
Early online date2 Oct 2023
DOIs
Publication statusPublished - Jan 2024

Bibliographical note

Funding Information:
This research was supported by TOP-PUNT grant 718.015.003 of the Netherlands Organization for Scientific Research (to G.-J.B.) and ERC-ADG grant 101020769 of the European Commission (to G.-J.B.). R.H. was funded by the GBS/CIDP Foundation International and the T2B collaboration project funded by PPP Allowance made available by Top Sector Life Sciences & Health to Samenwerkende Gezondheidsfondsen (SGF) under project number LSHM18055-SGF.

Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Nature Limited.

Funding

This research was supported by TOP-PUNT grant 718.015.003 of the Netherlands Organization for Scientific Research (to G.-J.B.) and ERC-ADG grant 101020769 of the European Commission (to G.-J.B.). R.H. was funded by the GBS/CIDP Foundation International and the T2B collaboration project funded by PPP Allowance made available by Top Sector Life Sciences & Health to Samenwerkende Gezondheidsfondsen (SGF) under project number LSHM18055-SGF.

FundersFunder number
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Netherlands Organisation for Scientific Research)718.015.003
TOP-PUNT
Netherlands Organization for Scientific Research101020769
ERC-AdGLSHM18055-SGF
European Commission - GBS/CIDP Foundation International
European Research Council (ERC)101020769

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Fingerprint

    Dive into the research topics of 'Chemoenzymatic synthesis of human natural killer-1-containing glycans and application as serum antibodies probes'. Together they form a unique fingerprint.

    Cite this